{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T20:27:04Z","timestamp":1751920024004,"version":"3.37.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ecole de l\u2019Inserm Liliane-Bettencourt"},{"name":"Fondation Bettencourt-Schueller"},{"name":"INSERM DR PARIS IDF CENTRE NORD"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79239-9","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T13:44:57Z","timestamp":1733233497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evidence for therapeutic use of cannabidiol for nail-patella syndrome-induced pain in a real-world pilot study"],"prefix":"10.1038","volume":"14","author":[{"given":"Thibaud","family":"Lebret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9verine","family":"Hatton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Callebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Cormier-Daire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4259-6861","authenticated-orcid":false,"given":"C\u00e9line","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"79239_CR1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/jgc4.1153","volume":"28","author":"L Geerts-Crabbe","year":"2019","unstructured":"Geerts-Crabbe, L. et al. Difficulties adapting to nail-Patella syndrome: a qualitative study of patients\u2019 perspectives. J. Genet. Couns. 28, 1011\u20131020. https:\/\/doi.org\/10.1002\/jgc4.1153 (2019).","journal-title":"J. Genet. Couns."},{"key":"79239_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00467-002-0911-5","volume":"17","author":"EM Bongers","year":"2002","unstructured":"Bongers, E. M., Gubler, M. C. & Knoers, N. V. Nail-patella syndrome. Overview on clinical and molecular findings. Pediatr. Nephrol. 17, 703\u2013712. https:\/\/doi.org\/10.1007\/s00467-002-0911-5 (2002).","journal-title":"Pediatr. Nephrol."},{"key":"79239_CR3","unstructured":"Sweeney, E. et al. in GeneReviews((R)) (eds M. P. Adam (1993)."},{"key":"79239_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00424-017-2013-z","volume":"469","author":"R Witzgall","year":"2017","unstructured":"Witzgall, R. Nail-patella syndrome. Pflugers Arch. 469, 927\u2013936. https:\/\/doi.org\/10.1007\/s00424-017-2013-z (2017).","journal-title":"Pflugers Arch."},{"key":"79239_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajmg.b.31138","volume":"156B","author":"C Lopez-Arvizu","year":"2011","unstructured":"Lopez-Arvizu, C. et al. Increased symptoms of attention deficit hyperactivity disorder and major depressive disorder symptoms in nail-patella syndrome: potential association with LMX1B loss-of-function. Am. J. Med. Genet. B Neuropsychiatr Genet. 156B, 59\u201366. https:\/\/doi.org\/10.1002\/ajmg.b.31138 (2011).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr Genet."},{"key":"79239_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.bpb.0000043727.21564.e9","volume":"12","author":"JL Beguiristain","year":"2003","unstructured":"Beguiristain, J. L., de Rada, P. D. & Barriga, A. Nail-patella syndrome: long term evolution. J. Pediatr. Orthop. B. 12, 13\u201316. https:\/\/doi.org\/10.1097\/01.bpb.0000043727.21564.e9 (2003).","journal-title":"J. Pediatr. Orthop. B"},{"key":"79239_CR7","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.otsr.2013.03.031","volume":"99","author":"S Lippacher","year":"2013","unstructured":"Lippacher, S., Mueller-Rossberg, E., Reichel, H. & Nelitz, M. Correction of malformative patellar instability in patients with nail-patella syndrome: a case report and review of the literature. Orthop. Traumatol. Surg. Res. 99, 749\u2013754. https:\/\/doi.org\/10.1016\/j.otsr.2013.03.031 (2013).","journal-title":"Orthop. Traumatol. Surg. Res."},{"key":"79239_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1440-169X.2008.01083.x","volume":"51","author":"JX Dai","year":"2009","unstructured":"Dai, J. X., Johnson, R. L. & Ding, Y. Q. Manifold functions of the nail-Patella syndrome gene Lmx1b in vertebrate development. Dev. Growth Differ. 51, 241\u2013250. https:\/\/doi.org\/10.1111\/j.1440-169X.2008.01083.x (2009).","journal-title":"Dev. Growth Differ."},{"key":"79239_CR9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nn1104","volume":"6","author":"YQ Ding","year":"2003","unstructured":"Ding, Y. Q. et al. Lmx1b is essential for the development of serotonergic neurons. Nat. Neurosci. 6, 933\u2013938. https:\/\/doi.org\/10.1038\/nn1104 (2003).","journal-title":"Nat. Neurosci."},{"key":"79239_CR10","doi-asserted-by":"publisher","first-page":"E4387","DOI":"10.1073\/pnas.1520387113","volume":"113","author":"H Doucet-Beaupre","year":"2016","unstructured":"Doucet-Beaupre, H. et al. Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons. Proc. Natl. Acad. Sci. U S A. 113, E4387\u20134396. https:\/\/doi.org\/10.1073\/pnas.1520387113 (2016).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"79239_CR11","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fnmol.2019.00062","volume":"12","author":"I Wever","year":"2019","unstructured":"Wever, I., Largo-Barrientos, P., Hoekstra, E. J. & Smidt, M. P. Lmx1b influences correct post-mitotic coding of mesodiencephalic dopaminergic neurons. Front. Mol. Neurosci. 12, 62. https:\/\/doi.org\/10.3389\/fnmol.2019.00062 (2019).","journal-title":"Front. Mol. Neurosci."},{"key":"79239_CR12","doi-asserted-by":"publisher","first-page":"12413","DOI":"10.1523\/JNEUROSCI.1077-11.2011","volume":"31","author":"CH Yan","year":"2011","unstructured":"Yan, C. H., Levesque, M., Claxton, S., Johnson, R. L. & Ang, S. L. Lmx1a and lmx1b function cooperatively to regulate proliferation, specification, and differentiation of midbrain dopaminergic progenitors. J. Neurosci. 31, 12413\u201312425. https:\/\/doi.org\/10.1523\/JNEUROSCI.1077-11.2011 (2011).","journal-title":"J. Neurosci."},{"key":"79239_CR13","doi-asserted-by":"publisher","first-page":"12781","DOI":"10.1523\/JNEUROSCI.4143-06.2006","volume":"26","author":"ZQ Zhao","year":"2006","unstructured":"Zhao, Z. Q. et al. Lmx1b is required for maintenance of central serotonergic neurons and mice lacking central serotonergic system exhibit normal locomotor activity. J. Neurosci. 26, 12781\u201312788. https:\/\/doi.org\/10.1523\/JNEUROSCI.4143-06.2006 (2006).","journal-title":"J. Neurosci."},{"key":"79239_CR14","doi-asserted-by":"publisher","first-page":"Doc16","DOI":"10.3205\/000201","volume":"12","author":"J Albishri","year":"2014","unstructured":"Albishri, J. Arthropathy and proteinuria: nail-patella syndrome revisited. Ger. Med. Sci. 12, Doc16. https:\/\/doi.org\/10.3205\/000201 (2014).","journal-title":"Ger. Med. Sci."},{"key":"79239_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/sj.ejhg.5201332","volume":"13","author":"JA Dunston","year":"2005","unstructured":"Dunston, J. A. et al. A neurological phenotype in nail patella syndrome (NPS) patients illuminated by studies of murine Lmx1b expression. Eur. J. Hum. Genet. 13, 330\u2013335. https:\/\/doi.org\/10.1038\/sj.ejhg.5201332 (2005).","journal-title":"Eur. J. Hum. Genet."},{"key":"79239_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/spc.0000000000000207","volume":"10","author":"K Bannister","year":"2016","unstructured":"Bannister, K. & Dickenson, A. H. What do monoamines do in pain modulation? Curr. Opin. Support Palliat. Care. 10, 143\u2013148. https:\/\/doi.org\/10.1097\/spc.0000000000000207 (2016).","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"79239_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/SPC.0000000000000055","volume":"8","author":"MH Ossipov","year":"2014","unstructured":"Ossipov, M. H., Morimura, K. & Porreca, F. Descending pain modulation and chronification of pain. Curr. Opin. Support Palliat. Care. 8, 143\u2013151. https:\/\/doi.org\/10.1097\/SPC.0000000000000055 (2014).","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"79239_CR18","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/mp.2015.216","volume":"21","author":"S Georgin-Lavialle","year":"2016","unstructured":"Georgin-Lavialle, S. et al. Mast cells\u2019 involvement in inflammation pathways linked to depression: evidence in mastocytosis. Mol. Psychiatry. 21, 1511\u20131516. https:\/\/doi.org\/10.1038\/mp.2015.216 (2016).","journal-title":"Mol. Psychiatry"},{"key":"79239_CR19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jpain.2008.12.006","volume":"10","author":"KC Light","year":"2009","unstructured":"Light, K. C. et al. Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder. J. Pain. 10, 542\u2013552. https:\/\/doi.org\/10.1016\/j.jpain.2008.12.006 (2009).","journal-title":"J. Pain"},{"key":"79239_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/jrms.JRMS_859_17","volume":"23","author":"MSM Al-Nimer","year":"2018","unstructured":"Al-Nimer, M. S. M., Mohammad, T. A. M. & Alsakeni, R. A. Serum levels of serotonin as a biomarker of newly diagnosed fibromyalgia in women: its relation to the platelet indices. J. Res. Med. Sci. 23, 71. https:\/\/doi.org\/10.4103\/jrms.JRMS_859_17 (2018).","journal-title":"J. Res. Med. Sci."},{"key":"79239_CR21","doi-asserted-by":"publisher","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","volume":"3","author":"O Hermine","year":"2008","unstructured":"Hermine, O. et al. Case-control cohort study of patients\u2019 perceptions of disability in mastocytosis. PLoS One. 3, e2266. https:\/\/doi.org\/10.1371\/journal.pone.0002266 (2008).","journal-title":"PLoS One"},{"key":"79239_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41584-020-00506-w","volume":"16","author":"P Sarzi-Puttini","year":"2020","unstructured":"Sarzi-Puttini, P., Giorgi, V., Marotto, D. & Atzeni, F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat. Rev. Rheumatol. 16, 645\u2013660 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"79239_CR23","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1097\/j.pain.0000000000002266","volume":"162","author":"S Haroutounian","year":"2021","unstructured":"Haroutounian, S. et al. International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 162, S117\u2013s124. https:\/\/doi.org\/10.1097\/j.pain.0000000000002266 (2021).","journal-title":"Pain"},{"key":"79239_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pnpbp.2012.01.007","volume":"38","author":"A Dogrul","year":"2012","unstructured":"Dogrul, A., Seyrek, M., Yalcin, B. & Ulugol, A. Involvement of descending serotonergic and noradrenergic pathways in CB1 receptor-mediated antinociception. Prog Neuropsychopharmacol. Biol. Psychiatry. 38, 97\u2013105. https:\/\/doi.org\/10.1016\/j.pnpbp.2012.01.007 (2012).","journal-title":"Prog Neuropsychopharmacol. Biol. Psychiatry"},{"key":"79239_CR25","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","volume":"30","author":"EB Russo","year":"2005","unstructured":"Russo, E. B., Burnett, A., Hall, B. & Parker, K. K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 30, 1037\u20131043. https:\/\/doi.org\/10.1007\/s11064-005-6978-1 (2005).","journal-title":"Neurochem Res."},{"key":"79239_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee, R. G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153, 199\u2013215. https:\/\/doi.org\/10.1038\/sj.bjp.0707442 (2008).","journal-title":"Br. J. Pharmacol."},{"key":"79239_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-neuro-070815-014038","volume":"39","author":"NE Zlebnik","year":"2016","unstructured":"Zlebnik, N. E. & Cheer, J. F. Beyond the CB1 receptor: is Cannabidiol the answer for disorders of Motivation? Annu. Rev. Neurosci. 39, 1\u201317. https:\/\/doi.org\/10.1146\/annurev-neuro-070815-014038 (2016).","journal-title":"Annu. Rev. Neurosci."},{"key":"79239_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1213\/ANE.0b013e3182707859","volume":"116","author":"TR Romero","year":"2013","unstructured":"Romero, T. R., Resende, L. C., Guzzo, L. S. & Duarte, I. D. CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system. Anesth. Analg. 116, 463\u2013472. https:\/\/doi.org\/10.1213\/ANE.0b013e3182707859 (2013).","journal-title":"Anesth. Analg"},{"key":"79239_CR29","doi-asserted-by":"publisher","unstructured":"Rezende, B., Alencar, A. K. N., de Bem, G. F., Fontes-Dantas, F. L. & Montes, G. C. Endocannabinoid System: chemical characteristics and biological activity. Pharmaceuticals (Basel). 16. https:\/\/doi.org\/10.3390\/ph16020148 (2023).","DOI":"10.3390\/ph16020148"},{"key":"79239_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0014-2999(02)02624-9","volume":"456","author":"RG Pertwee","year":"2002","unstructured":"Pertwee, R. G., Ross, R. A., Craib, S. J. & Thomas, A. -)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur. J. Pharmacol. 456, 99\u2013106. https:\/\/doi.org\/10.1016\/s0014-2999(02)02624-9 (2002).","journal-title":"Eur. J. Pharmacol."},{"key":"79239_CR31","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.3390\/ph3082647","volume":"3","author":"M Jenny","year":"2010","unstructured":"Jenny, M., Schrocksnadel, S., Uberall, F. & Fuchs, D. The potential role of cannabinoids in modulating Serotonergic Signaling by their influence on Tryptophan Metabolism. Pharmaceuticals (Basel). 3, 2647\u20132660. https:\/\/doi.org\/10.3390\/ph3082647 (2010).","journal-title":"Pharmaceuticals (Basel)"},{"key":"79239_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1177\/1203475417738971","volume":"22","author":"G Dhadwal","year":"2018","unstructured":"Dhadwal, G. & Kirchhof, M. G. The risks and benefits of Cannabis in the Dermatology Clinic. J. Cutan. Med. Surg. 22, 194\u2013199. https:\/\/doi.org\/10.1177\/1203475417738971 (2018).","journal-title":"J. Cutan. Med. Surg."},{"key":"79239_CR33","doi-asserted-by":"publisher","first-page":"E295","DOI":"10.1002\/ajh.27049","volume":"98","author":"L Mayrand","year":"2023","unstructured":"Mayrand, L. et al. Dramatic efficacy of cannabidiol on refractory chronic pain in an adolescent with sickle cell disease. Am. J. Hematol. 98, E295\u2013E297. https:\/\/doi.org\/10.1002\/ajh.27049 (2023).","journal-title":"Am. J. Hematol."},{"key":"79239_CR34","doi-asserted-by":"publisher","unstructured":"Rossignol, J., Hatton, S., Ridley, A., Hermine, O. & Greco, C. The effectiveness and safety of Pharmaceutical-Grade Cannabidiol in the treatment of Mastocytosis-Associated Pain: a pilot study. Biomedicines. 11 https:\/\/doi.org\/10.3390\/biomedicines11020520 (2023).","DOI":"10.3390\/biomedicines11020520"},{"key":"79239_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1300\/J175v02n01_02","volume":"2","author":"E Russo","year":"2002","unstructured":"Russo, E. et al. Chronic cannabis use in the compassionate investigational New Drug program: an examination of benefits and adverse effects of legal clinical Cannabis. J. Cannabis Ther. 2, 3\u201357 (2002).","journal-title":"J. Cannabis Ther."},{"key":"79239_CR36","doi-asserted-by":"publisher","unstructured":"Strand, N. H. et al. Cannabis for the treatment of Fibromyalgia: a systematic review. Biomedicines. 11 https:\/\/doi.org\/10.3390\/biomedicines11061621 (2023).","DOI":"10.3390\/biomedicines11061621"},{"key":"79239_CR37","doi-asserted-by":"publisher","unstructured":"Souza, J. D. R. et al. Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020\u20132022). Pharmaceutics 14, doi: (2022). https:\/\/doi.org\/10.3390\/pharmaceutics14122598","DOI":"10.3390\/pharmaceutics14122598"},{"key":"79239_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000515042","volume":"4","author":"R Verma","year":"2021","unstructured":"Verma, R. et al. Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: preclinical and clinical-based evidence. Med. Cannabis Cannabinoids. 4, 43\u201360. https:\/\/doi.org\/10.1159\/000515042 (2021).","journal-title":"Med. Cannabis Cannabinoids"},{"key":"79239_CR39","doi-asserted-by":"publisher","first-page":"e26913","DOI":"10.7759\/cureus.26913","volume":"14","author":"MRB Villanueva","year":"2022","unstructured":"Villanueva, M. R. B. et al. Efficacy, Safety, and regulation of Cannabidiol on Chronic Pain: a systematic review. Cureus. 14, e26913. https:\/\/doi.org\/10.7759\/cureus.26913 (2022).","journal-title":"Cureus"},{"key":"79239_CR40","doi-asserted-by":"publisher","unstructured":"Paredes, S., Cantillo, S., Candido, K. D. & Knezevic, N. N. An Association of Serotonin with Pain disorders and its modulation by Estrogens. Int. J. Mol. Sci. 20 https:\/\/doi.org\/10.3390\/ijms20225729 (2019).","DOI":"10.3390\/ijms20225729"},{"key":"79239_CR41","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s10072-014-1867-5","volume":"35","author":"G D\u2019Andrea","year":"2014","unstructured":"D\u2019Andrea, G. et al. Tryptamine levels are low in plasma of chronic migraine and chronic tension-type headache. Neurol. Sci. 35, 1941\u20131945. https:\/\/doi.org\/10.1007\/s10072-014-1867-5 (2014).","journal-title":"Neurol. Sci."},{"key":"79239_CR42","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/rheumatology\/40.3.290","volume":"40","author":"E Legangneux","year":"2001","unstructured":"Legangneux, E. et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatol. (Oxford). 40, 290\u2013296. https:\/\/doi.org\/10.1093\/rheumatology\/40.3.290 (2001).","journal-title":"Rheumatol. (Oxford)"},{"key":"79239_CR43","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jpain.2015.01.007","volume":"16","author":"AJ Parent","year":"2015","unstructured":"Parent, A. J. et al. Relationship between blood- and cerebrospinal fluid-bound neurotransmitter concentrations and conditioned pain modulation in pain-free and chronic pain subjects. J. Pain. 16, 436\u2013444. https:\/\/doi.org\/10.1016\/j.jpain.2015.01.007 (2015).","journal-title":"J. Pain"},{"key":"79239_CR44","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/AJP.0b013e31820dfede","volume":"27","author":"E Paul-Savoie","year":"2011","unstructured":"Paul-Savoie, E. et al. A deficit in peripheral serotonin levels in major depressive disorder but not in chronic widespread pain. Clin. J. Pain. 27, 529\u2013534. https:\/\/doi.org\/10.1097\/AJP.0b013e31820dfede (2011).","journal-title":"Clin. J. Pain"},{"key":"79239_CR45","doi-asserted-by":"publisher","first-page":"722","DOI":"10.2337\/diacare.16.5.722","volume":"16","author":"C Tsigos","year":"1993","unstructured":"Tsigos, C., Reed, P., Weinkove, C., White, A. & Young, R. J. Plasma norepinephrine in sensory diabetic polyneuropathy. Diabetes Care. 16, 722\u2013727. https:\/\/doi.org\/10.2337\/diacare.16.5.722 (1993).","journal-title":"Diabetes Care"},{"key":"79239_CR46","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/ALN.0000000000000749","volume":"123","author":"I Martins","year":"2015","unstructured":"Martins, I. et al. Increased noradrenergic neurotransmission to a pain facilitatory area of the brain is implicated in facilitation of chronic pain. Anesthesiology. 123, 642\u2013653. https:\/\/doi.org\/10.1097\/ALN.0000000000000749 (2015).","journal-title":"Anesthesiology"},{"key":"79239_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejphar.2006.08.064","volume":"551","author":"H Wei","year":"2006","unstructured":"Wei, H. & Pertovaara, A. Spinal and pontine alpha2-adrenoceptors have opposite effects on pain-related behavior in the neuropathic rat. Eur. J. Pharmacol. 551, 41\u201349. https:\/\/doi.org\/10.1016\/j.ejphar.2006.08.064 (2006).","journal-title":"Eur. J. Pharmacol."},{"key":"79239_CR48","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1111\/ejn.12690","volume":"40","author":"AM Cathel","year":"2014","unstructured":"Cathel, A. M. et al. Cannabinoid modulation of alpha2 adrenergic receptor function in rodent medial prefrontal cortex. Eur. J. Neurosci. 40, 3202\u20133214. https:\/\/doi.org\/10.1111\/ejn.12690 (2014).","journal-title":"Eur. J. Neurosci."},{"key":"79239_CR49","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/s0006-8993(03)03324-9","volume":"987","author":"T Gutierrez","year":"2003","unstructured":"Gutierrez, T. et al. Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Res. 987, 176\u2013185. https:\/\/doi.org\/10.1016\/s0006-8993(03)03324-9 (2003).","journal-title":"Brain Res."},{"key":"79239_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jneuroim.2008.12.004","volume":"207","author":"M Jenny","year":"2009","unstructured":"Jenny, M., Santer, E., Pirich, E., Schennach, H. & Fuchs, D. Delta9-tetrahydrocannabinol and cannabidiol modulate mitogen-induced tryptophan degradation and neopterin formation in peripheral blood mononuclear cells in vitro. J. Neuroimmunol. 207, 75\u201382. https:\/\/doi.org\/10.1016\/j.jneuroim.2008.12.004 (2009).","journal-title":"J. Neuroimmunol."},{"key":"79239_CR51","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40262-019-00841-6","volume":"59","author":"B Tayo","year":"2020","unstructured":"Tayo, B. et al. Parallel-Group, single-dose trial of the Pharmacokinetics, Safety, and tolerability of Cannabidiol in subjects with mild to severe renal impairment. Clin. Pharmacokinet. 59, 747\u2013755. https:\/\/doi.org\/10.1007\/s40262-019-00841-6 (2020).","journal-title":"Clin. Pharmacokinet."},{"key":"79239_CR52","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1053\/j.ajkd.2017.08.001","volume":"70","author":"B Najafian","year":"2017","unstructured":"Najafian, B., Smith, K., Lusco, M. A., Alpers, C. E. & Fogo, A. B. AJKD Atlas of Renal Pathology: nail-Patella syndrome\u2013Associated Nephropathy. Am. J. Kidney Dis. 70, e19\u2013e20 (2017).","journal-title":"Am. J. Kidney Dis."},{"key":"79239_CR53","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware, J. E. Jr. & Sherbourne, C. D. The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med. Care. 30, 473\u2013483 (1992).","journal-title":"Med. Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79239-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79239-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79239-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T14:12:12Z","timestamp":1733235132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79239-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79239"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79239-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the patients enrolled in this prospective study, or their legal guardian for patients aged\u2009\u2264\u200918 years, provided written informed consent for the publication of their data included in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The institutional review board of the reference center for constitutional bone diseases, the MOC-Necker-Hospital (Paris, France), approved the study. In line with the French legislation on studies conducted in routine clinical practice, the study protocol was registered by the Assistance Publique\u2013H\u00f4pitaux de Paris the 16\/05\/2022 under the following reference: MR004-2022-0516123418.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board Statement"}}],"article-number":"30105"}}